Wednesday, February 1, 2023
| Characteristic | V. alginolyticus | V. parahaemolyticus | V. cholerae non-O1/O139 | V. vulnificus | Other species |
|---|---|---|---|---|---|
| Total patients | 23 (100) | 20 (100) | 10 (100) | 7 (100) | 7 (100) |
| Demographics | |||||
| Age, y, median (SD) | 50 (+26.7) | 53 (+22.8) | 69 (+19.7) | 66 (+11.5) | 40 (+24.8) |
| Sex | |||||
| M | 19 (83) | 15 (75) | 7 (70) | 7 (100) | 6 (86) |
| F | 4 (17) | 5 (25) | 3 (30) | 0 | 1 (14) |
| Underlying condition | |||||
| Heart failure | 8 (35) | 6 (30) | 5 (50) | 4 (57) | 1 (14) |
| Neoplasia | 1 (4) | 5 (25) | 4 (40) | 0 (0) | 1 (14) |
| Diabetes | 2 (9) | 3 (15) | 1 (10) | 1 (14) | 1 (14) |
| Kidney failure | 2 (9) | 1 (5) | 1 (10) | 0 | 3 (43) |
| Immune disease | 2 (9) | 2 (10) | 1 (10) | 0 | 2 (29) |
| Hemopathy | 1 (4) | 1 (5) | 1 (10) | 1 (14) | 1 (14) |
| Liver disease | 1 (4) | 1 (5) | 2 (20) | 1 (14) | 0 |
| Alcohol use disorder | 2 (9) | 1 (5) | 2 (20) | 2 (29) | 0 |
| Preexisting wound | 3 (13) | 0 | 0 | 3 (43) | 0 |
| Digestive surgery | 2 (9) | 2 (10) | 1 (10) | 0 | 1 (14) |
| Time to symptom onset, d, median (SD) | 2.4 (+2.0) | 1.3 (+0.9) | 3 (+4.4) | 5.6 (+8.1) | 1 (+0.0) |
| Infection type | |||||
| Acute | 14 (61) | 19 (95) | 10 (100) | 7 (100) | 5 (71) |
| Chronic | 9 (39) | 1 (5) | 0 | 0 | 2 (29) |
| Outcome | |||||
| Recovered | 21 (91) | 17 (85) | 8 (80) | 6 (86) | 7 (100) |
| Died | 2 (9) | 3 (15) | 2 (20) | 1 (14) | 0 |
Table 1. Clinical characteristics of patients with Vibrio infection, by species, Bay of Biscay, France, 2001–2019*
*Values are no. (%) except as indicated.
| Antibiotic | V. alginolyticus | V. parahaemolyticus | V. cholerae non-O1/O139 | V. vulnificus | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S | I | R | S | I | R | S | I | R | S | I | R | ||||
| Amoxicillin | 1 | 0 | 15 | 1 | 6 | 7 | 2 | 2 | 3 | 5 | 0 | 0 | |||
| Ticarcillin | 5 | 0 | 10 | 2 | 2 | 9 | 5 | 0 | 1 | 5 | 0 | 0 | |||
| First-generation cephalosporin | 10 | 4 | 0 | 13 | 1 | 0 | 4 | 1 | 0 | 4 | 1 | 0 | |||
Table 2. Available drug-susceptibility test results for the main antibiotics used to treat Vibrio infections, by species, Bay of Biscay, France, 2001–2019*
*Data are no. of cases. I, intermediate; R, resistant; S, susceptible.
| Characteristic | No sepsis, n = 42 | Septic shock, n = 13 | p value | ||||
|---|---|---|---|---|---|---|---|
| No. | % (95% CI) | No. | % (95% CI) | ||||
| Patient sex | |||||||
| M | 35 | 83 (72–95) | 10 | 77 (54–100) | 0.685 | ||
| F | 7 | 17 (5–28) | 3 | 23 (0.2–46) | |||
| Underlying conditions | |||||||
| Heart failure | 18 | 43 (28–58) | 6 | 46 (19–73) | Referent | ||
| Neoplasia | 6 | 14 (4–25) | 4 | 31 (6–56) | 0.223 | ||
| Diabetes | 7 | 17 (5–28) | 1 | 8 (0–22) | 0.664 | ||
| Kidney failure | 5 | 12 (2–22) | 2 | 15 (0–35) | 0.664 | ||
| Immune disease | 5 | 12 (2–22) | 2 | 15 (0–35) | 0.664 | ||
| Hemopathy | 3 | 7 (0–15) | 2 | 15 (0–35) | 0.582 | ||
| Liver disease | 2 | 5 (0–11) | 3 | 23 (0–46) | 0.318 | ||
| Alcohol use disorder | 3 | 7 (0–15) | 4 | 31 (6–56) | 0.102 | ||
| Preexisting wound | 6 | 14 (4–25) | 0 | 0 (0–0) | 0.317 | ||
| Digestive surgery | 4 | 10 (1–18) | 2 | 15 (0–35) | 0.618 | ||
| Species | |||||||
| V. alginolyticus | 10 | 24 (11–37) | 4 | 31 (6–56) | |||
| V. parahaemolyticus | 14 | 33 (19–48) | 5 | 38 (12–65) | |||
| V. cholerae non-O1/O139 | 8 | 19 (7–31) | 2 | 15 (0–35) | |||
| V. vulnificus | 6 | 14 (4–25) | 1 | 8 (0–22) | |||
| Other Vibrio species | 4 | 10 (1–18) | 1 | 8 (0–22) | |||
| Outcome | |||||||
| Recovered | 40 | 95 (89–100) | 7 | 54 (27–81) | 0.001 | ||
| Died | 2 | 5 (0–11) | 6 | 46 (19–73) | |||
Table 3. Clinical characteristics and outcome of patients with and without septic shock after acute Vibrio infection, Bay of Biscay, France, 2001–2019*
*Median patient age ( + SD) was 60 ( + 21.4) for no sepsis and 61 ( + 15.3) for septic shock.
Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 1.00 ABIM MOC points
This activity is intended for primary care physicians, infectious disease specialists, and other clinicians who treat and manage patients who may become infected with Vibrio spp.
The goal of this activity is to assess the epidemiology, microbiology, and prognosis of infection with Vibrio spp.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC Released: 11/18/2022
Valid for credit through: 11/18/2023
processing....
| « Return to: Clinical and Epidemiologic Characteristics and Therapeutic Management of Patients With Vibrio Infections, Bay of Biscay, France, 2001–2019 |
